Skip to main content

German's IDT to make 10M AstraZeneca vaccine doses in 2021

Friday, April 16, 2021 | The Associated Press

BERLIN (AP) — German vaccine-maker IDT Biologika said Friday it plans to bottle this year some 10 million doses of the coronavirus shot developed by AstraZeneca.

IDT Biologika and AstraZeneca previously announced they would expand production capacity for the British-Swedish company's vaccine at a plant in the German town of Dessau by the end of 2022.

The new agreement was made possible because a third manufacturer, Merz Pharma, relinquished the production capacity it had reserved with IDT for the second quarter.

IDT produces vaccines for several pharmaceutical companies. In March, the company announced that for three months it would make the single-dose COVID-19 shot developed by Johnson & Johnson.

Chief Executive Officer Juergen Betzing said Friday that IDT was also in talks with the developers of Russia's Sputnik V shot, which has yet to be approved for use in the European Union.

The AstraZeneca vaccine is restricted to people over 60 in Germany due to concerns over rare blood clots in some recipients. Among those who received it recently are German Chancellor Angela Merkel and President Frank-Walter Steinmeier.

Featured Article: Moving Average - How it Helps Investors in Stock Selection


7 Electric Vehicle (EV) Stocks That Have Real Juice

I’ll start with a disclaimer. You won’t see Tesla (NASDAQ:TSLA) or Nio (NYSE:NIO) on this list. And that’s not because I’m being contrarian. I just view Tesla and Nio as the known quantities in the electric vehicle sector. The goal of this presentation is to help you identify stocks that may be flying under your radar.

Many EV stocks went public in 2020 via a special purpose acquisition company (SPAC). There is both good and bad to that story. The good is that investors have many options for investing in the EV sector. Many of the companies that have entered the market are attempting to carve out a specific niche.

The potentially bad news is that these stocks are very speculative in nature. Whereas companies like Tesla and Nio have a proven (albeit recent) track record, there are things like revenue and orders that investors can analyze. With many of these newly public companies, investors are being asked to buy the story more than the stock and that is always risky.

However, in this special presentation, we’ve identified seven companies that look like they have a story that is compelling enough that investors should be rewarded in 2021.

View the "7 Electric Vehicle (EV) Stocks That Have Real Juice".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)2.3$171.03+0.5%2.36%26.89Buy$185.70
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.